12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ixazomib: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 50 evaluable patients with relapsed and/or refractory MM who received >=2 prior therapies showed that once-weekly oral MLN9708 led to an overall response rate (ORR) of 18%, including 1 very good partial response and 8...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >